SKINBIOTHERAPEUTICS PLC
SKINBIOTHERAPEUTICS PLC is a public limited company registered in England and Wales under company number 09632164, according to Companies House. Incorporated on 10 June 2015 as Skinbiotix Ltd, the company was renamed SkinBiotherapeutics Ltd and re-registered as a public limited company under its current name, SkinBiotherapeutics PLC, both on 23 December 2016. It is recorded with an “Active” status, with its registered office at The Core, Bath Lane, Newcastle Helix, Newcastle Upon Tyne, NE4 5TF, and is classified by Companies House under UK Standard Industrial Classification code 86900 (other human health activities).
SkinBioTherapeutics plc is a life-sciences company that researches, develops and commercialises microbiome-derived technologies for skin, scalp and gut health, operating through its SkinBiotix, AxisBiotix-Ps, MediBiotix, CleanBiotix and PharmaBiotix technology platforms together with its Dermatonics and Bio-Tech Solutions trading subsidiaries, and holds a development partnership with Croda Europe Limited covering skincare and cosmetic applications of its SkinBiotix ingredient technology. For the year ended 30 June 2025, the group reported restated consolidated revenue of £3.87 million, down from an initially reported £4.64 million after a board investigation found that supporting documentation for £0.77 million of accrued royalty revenue had been fabricated by the company’s then chief executive; for the six months ended 31 December 2025, group revenue rose 37.4% to £2.17 million, with an operating loss of £1.00 million and a period-end cash balance of £3.1 million.
SkinBioTherapeutics plc’s ordinary shares trade on AIM, a market operated by the London Stock Exchange, under the ticker SBTX, with 259,168,671 ordinary shares of 1 pence each in issue as at 1 April 2026. Between February and June 2026 the company underwent substantial board and executive change: chief executive Stuart Ashman resigned on 13 February 2026 following suspension pending a board investigation into his conduct; Rachel Parsonage was appointed director and interim chief executive on 9 March 2026; and on 8 June 2026, alongside the restated FY2025 results, the company announced the departures of chair Martin Hunt and non-executive director Catherine Prescott from the board, together with the scheduled 30 June 2026 departure of chief financial officer Emily Bertram.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of SKINBIOTHERAPEUTICS PLC
SkinBioTherapeutics plc’s ordinary shares are admitted to trading on AIM. Companies House records a persons-with-significant-control statement, filed 21 October 2021, that the company knows or has reasonable cause to believe there is no registrable person or registrable relevant legal entity in relation to the company; an earlier registered PSC, Optibiotix Health Plc (a UK public company, registration number 05880755), which held more than 25% but not more than 50% of shares and voting rights, ceased to be a PSC on 2 November 2020. As at 1 April 2026, according to the company’s own investor relations disclosure, SkinBioTherapeutics plc’s issued share capital comprised 259,168,671 ordinary shares of 1 pence each. Major shareholdings disclosed above 3% of the issued capital were: Mark and Diana Dixon, held jointly, 76,000,000 shares (29.324%); David Brierwood, 16,539,989 shares (6.38%); Tyndall Investment Management, 15,223,381 shares (5.87%); Seneca Partners Limited, 8,409,913 shares (3.24%); and Unicorn Asset Management, 7,894,737 shares (3.05%). The company separately discloses that 41.6% of its issued share capital is not held in public hands, a figure it defines as including board members and shareholders holding more than 10% of the issued voting share capital.
Data availability
Classification: Major shareholders only. The current Companies House PSC register shows no registrable person or entity, last confirmed in October 2021, while the company’s own April 2026 investor disclosure shows a joint holding by Mark and Diana Dixon above the 25% level at which individual PSC registration would normally be expected; this profile does not resolve that discrepancy, which may reflect an interest split between two individuals each holding less than 25% in their own right, and no verified ultimate beneficial owner is reported as a result. Holdings below the company’s own 3% disclosure threshold are not reported here.
Sources
- Companies House – Persons with Significant Control, company number 09632164 (retrieved 11 September 2026)
- Companies House – Company overview, company number 09632164 (retrieved 11 September 2026)
- SkinBioTherapeutics plc – Shares in Issue and Shareholder Information, skinbiotherapeutics.com (as at 1 April 2026, retrieved 11 September 2026)
Officers
16
Directors and officers of SKINBIOTHERAPEUTICS PLC
Companies House records three active officer entries for SkinBioTherapeutics plc as at 11 September 2026: two directors and one corporate company secretary. The current board comprises Alyson Margaret Levett (appointed 1 January 2026) and Rachel Lisa Parsonage (appointed 9 March 2026, and identified in the company’s own announcements as interim chief executive officer); both are disclosed by Companies House as British nationals resident in England. The company secretary is MSP Corporate Services Limited (appointed 30 June 2026), a corporate officer registered in England and Wales under company number 11594637, at 27-28 Eastcastle Street, London, W1W 8DH. The register shows extensive officer turnover over the twelve months to 11 September 2026, including the resignations of former chief executive Stuart Ashman, former chair Martin Braddock Hunt, former non-executive director Catherine Denise Prescott, former director Danielle Bekker, and former chief financial officer and director Emily Lorraine Bertram, alongside a longer history of earlier appointments and resignations dating back to the company’s 2015 incorporation. This overview reflects officer data retrieved from Companies House on 11 September 2026.
Recent officer changes
- Stuart Ashman resigned as director and chief executive officer effective 13 February 2026, following his suspension by the board pending an investigation into his conduct, per Companies House filing and the company’s RNS announcement.
- Rachel Parsonage was appointed director and interim chief executive officer effective 9 March 2026, per Companies House filing and the company’s RNS announcement.
- Martin Hunt (chair) and Catherine Prescott (non-executive director) both resigned as directors effective 8 June 2026, alongside the company’s half-year and restated FY2025 results announcement, per Companies House filing and RNS.
Data availability
Classification: Full. Companies House publishes current and historical director and secretary appointment and resignation dates together with officially disclosed nationality and country of residence for individual directors, both currently recorded as British nationals resident in England. Occupation, as distinct from legal role, is not shown in the register extract reviewed for this profile, and the corporate company secretary is a legal entity rather than a natural person, so no nationality applies to it.
Sources
- Companies House – Officers list, company number 09632164 (retrieved 11 September 2026)
- Companies House – Company overview, company number 09632164 (retrieved 11 September 2026)
- SkinBioTherapeutics plc – Resignation of CEO, RNS announcement via Investegate, 13 February 2026 (retrieved 11 September 2026)
- SkinBioTherapeutics plc – Appointment of the Interim CEO to the Board, RNS announcement, 9 March 2026 (retrieved 11 September 2026)
- SkinBioTherapeutics plc – Half-year Results (HY26) and Restated FY25 Results, RNS announcement via Investegate, 8 June 2026 (retrieved 11 September 2026)
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of SKINBIOTHERAPEUTICS PLC
SkinBioTherapeutics plc is a publicly listed, AIM-quoted holding company that Companies House confirms as the registered person with significant control, through ownership of 75% or more of shares and voting rights and the right to appoint or remove directors, of seven UK subsidiaries: Pharmabiotix Limited, Medibiotix Limited, Dermatonics Ltd, Skinbiotix Limited, Axisbiotix Limited, Bio-Tech Solutions Limited and Cleanbiotix Limited, each individually verified against its own Companies House PSC filing. SkinBioTherapeutics plc itself has no current registered person with significant control: Companies House holds a statement, filed 21 October 2021, that the company knows of no registrable person or entity; an earlier PSC, Optibiotix Health Plc, which held more than 25% but not more than 50% of shares and voting rights, ceased to be a PSC on 2 November 2020 and is treated here as a historical relationship rather than a current parent. All seven verified subsidiaries and the parent company are registered in England and Wales; no subsidiaries outside the United Kingdom have been identified in the sources reviewed for this profile. Information is current as of 11 September 2026.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| PHARMABIOTIX LIMITED | United Kingdom | 12677528 | Direct subsidiary | 75% or more of shares and voting rights | Active | 11 September 2026 |
| MEDIBIOTIX LIMITED | United Kingdom | 12676346 | Direct subsidiary | 75% or more of shares and voting rights | Active | 11 September 2026 |
| DERMATONICS LTD | United Kingdom | 06472144 | Direct subsidiary | 75% or more of shares and voting rights | Active | 11 September 2026 |
| SKINBIOTIX LIMITED | United Kingdom | 10549152 | Direct subsidiary | 75% or more of shares (voting rights band not separately confirmed) | Active | 11 September 2026 |
| AXISBIOTIX LIMITED | United Kingdom | 12276227 | Direct subsidiary | 75% or more of shares (voting rights band not separately confirmed) | Active | 11 September 2026 |
| BIO-TECH SOLUTIONS LIMITED | United Kingdom | 04557084 | Direct subsidiary | 75% or more of shares and voting rights | Active | 11 September 2026 |
| CLEANBIOTIX LIMITED | United Kingdom | 12677256 | Direct subsidiary | 75% or more of shares and voting rights | Active | 11 September 2026 |
Recent structural changes
- SkinBioTherapeutics plc became the registered person with significant control of Dermatonics Ltd on 25 January 2024, replacing an individual PSC, per Companies House filing.
- SkinBioTherapeutics plc became the registered person with significant control of Bio-Tech Solutions Limited on 11 October 2024, replacing two individual PSCs, per Companies House filing.
- SkinBioTherapeutics plc’s own former PSC, Optibiotix Health Plc, ceased to hold significant control on 2 November 2020, since which date the company has had no registered controlling shareholder of its own, per Companies House filing.
Data availability
Classification: Full for the seven verified direct subsidiaries, each individually confirmed via its own Companies House PSC filing. No corporate ultimate parent above SkinBioTherapeutics plc has been identified, and the company’s own PSC register currently shows none. Ownership is reported at the percentage band disclosed by Companies House rather than as an exact figure.
Sources
- Companies House – Persons with Significant Control, company numbers 09632164, 12677528, 12676346, 06472144, 10549152, 12276227, 04557084 and 12677256 (retrieved 11 September 2026)
- Companies House – Company overview, company number 09632164 (retrieved 11 September 2026)
SKINBIOTHERAPEUTICS PLC
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does SKINBIOTHERAPEUTICS PLC do?
SKINBIOTHERAPEUTICS PLC (company number 09632164) is a public limited company registered in England and Wales, incorporated 10 June 2015 as Skinbiotix Ltd and re-registered as SkinBiotherapeutics PLC on 23 December 2016. Registered office: The Core, Bath Lane, Newcastle Helix, Newcastle Upon Tyne, NE4 5TF; SIC code 86900 (other human health activities). It is a life-sciences company researching, developing and commercialising microbiome-derived technologies for skin, scalp and gut health.
Who owns SKINBIOTHERAPEUTICS PLC?
Companies House currently records no registered person with significant control for SkinBioTherapeutics plc (statement filed 21 October 2021). As at 1 April 2026, the company disclosed major shareholders above 3% of issued capital: Mark and Diana Dixon jointly 29.324%, David Brierwood 6.38%, Tyndall Investment Management 5.87%, Seneca Partners Limited 3.24%, and Unicorn Asset Management 3.05%.
Who is SKINBIOTHERAPEUTICS PLC's UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) data is recorded for SKINBIOTHERAPEUTICS PLC; access to beneficial-ownership data in this jurisdiction is governed by its own register rules.
What is SKINBIOTHERAPEUTICS PLC's company registration number?
SKINBIOTHERAPEUTICS PLC's registration number is 09632164, filed with Companies House in United Kingdom. Its current status on the register is active.
Is SKINBIOTHERAPEUTICS PLC still an active company?
SKINBIOTHERAPEUTICS PLC's status on Companies House is listed as active.
When was SKINBIOTHERAPEUTICS PLC incorporated?
SKINBIOTHERAPEUTICS PLC was incorporated on 10 June 2015, according to Companies House.
What is SKINBIOTHERAPEUTICS PLC's registered address?
The registered address on file for SKINBIOTHERAPEUTICS PLC is Newcastle Upon Tyne, United Kingdom.
What legal structure is SKINBIOTHERAPEUTICS PLC registered as?
SKINBIOTHERAPEUTICS PLC is registered as a Public Limited Company in United Kingdom.
What is SKINBIOTHERAPEUTICS PLC's revenue?
For the year ended 30 June 2025, SkinBioTherapeutics plc reported restated consolidated group revenue of £3.87 million, down from an initially reported £4.64 million after a board investigation found £0.77 million of accrued royalty revenue had been supported by fabricated documentation. For the six months ended 31 December 2025, revenue rose 37.4% to £2.17 million, with an operating loss of £1.00 million and period-end cash of £3.1 million.
Is SKINBIOTHERAPEUTICS PLC listed on a stock exchange?
SkinBioTherapeutics plc's ordinary shares trade on AIM, a market operated by the London Stock Exchange, under ticker SBTX, with 259,168,671 ordinary shares of 1 pence each in issue as at 1 April 2026.
Who are the officers/directors of SKINBIOTHERAPEUTICS PLC?
Companies House records two active directors as at 11 September 2026: Alyson Margaret Levett (appointed 1 January 2026) and Rachel Lisa Parsonage (appointed 9 March 2026, interim chief executive), both British nationals resident in England, plus corporate secretary MSP Corporate Services Limited (appointed 30 June 2026). Former CEO Stuart Ashman resigned 13 February 2026 following a board conduct investigation; former chair Martin Hunt and former non-executive director Catherine Prescott resigned 8 June 2026.
Does SKINBIOTHERAPEUTICS PLC have a parent company or subsidiaries?
Companies House confirms SkinBioTherapeutics plc holds 75% or more of the shares and voting rights in seven verified UK subsidiaries: Pharmabiotix Limited, Medibiotix Limited, Dermatonics Ltd, Skinbiotix Limited, Axisbiotix Limited, Bio-Tech Solutions Limited and Cleanbiotix Limited. SkinBioTherapeutics plc itself has no current registered person with significant control; its former PSC, Optibiotix Health Plc, ceased to hold control on 2 November 2020.
Can Zavia monitor changes to SKINBIOTHERAPEUTICS PLC's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to SKINBIOTHERAPEUTICS PLC's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access SKINBIOTHERAPEUTICS PLC's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like SKINBIOTHERAPEUTICS PLC's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 8 September 2026.